A phase 1 open-label trial to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics, and immunogenicity of subcutaneous VIS171 in participants with autoimmune disease(s).

• Protocol code: VIS171-103
• EudraCT code: _
• Research group: Nephrology and kidney transplantation
• Service: Nephrology
• Principal investigator:  Sans Atxer, Laia
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase I

Estudio de fase 1b que combina dinutuximab beta (DB) con regímenes de quimioterapia de inducción en pacientes con neuroblastoma de alto riesgo de reciente diagnóstico.

• Protocol code: SIOPEN-PILOT01
• EudraCT code: No aplica
• Research group: Childhood Cancer and Blood Disorders
• Service: Pediatric Oncohematology
• Principal investigator:  Moreno Martín-Retortillo, Lucas
• Pathology: Tumors
• Phase: Fase I

A 2-Part, Randomized, Double-Blind, Placebo-Controlled Study in Participants with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping with an Initial Multiple Ascending Dose Part A to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENTR-601-45, Followed by Part B to Evaluate the Safety and Efficacy of ENTR-601-45 (ELEVATE-45)

• Protocol code: ENTR-601-45-201
• EudraCT code: _
• Research group: Therapeutics and Innovations in Neuropediatrics and other paediatric rare diseases
• Service: General Pediatrics and Specialties
• Principal investigator:  Gómez Andrés, David
• Pathology: Malalties del sistema nerviós
• Phase: Fase I

AFFIRM: A Randomized, double-blind, placebo-controlled, study to evaluate the effect of Seladelpar on clinical outcomes in patients with primary biliary cholangitis (PBC) and compensated cirrhosis.

• Protocol code: CB8025-41837
• EudraCT code: _
• Research group: Liver Diseases
• Service: Hepatology
• Principal investigator:  Villagrasa Vilella, Ares Aurora
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase III